Sotorasib in KRASG12C mutated lung cancer

被引：0
|
作者：
Olivier, Timothee [1 ]
Prasad, Vinay [2 ]
机构：
[1] Geneva Univ Hosp, Dept Oncol, CH-1205 Geneva, Switzerland
[2] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA
来源：
LANCET | 2024年 / 403卷 / 10422期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Sotorasib in KRASG12C mutated lung cancer - Authors' reply
    Paz-Ares, Luis
    Mehta, Bhakti
    Wang, Yang
    Obiozor, Cynthia
    Waterhouse, David
    de Langen, Adrianus Johannes
    LANCET, 2024, 403 (10422): : 145 - 146
  • [2] Sotorasib in KRASG12C mutated lung cance Reply
    Paz-Ares, Luis
    Mehta, Bhakti
    Wang, Yang
    Obiozor, Cynthia
    Waterhouse, David
    de Langen, Adrianus Johannes
    LANCET, 2024, 403 (10422): : 145 - 146
  • [3] Sotorasib: a KRASG12C inhibitor for non-small cell lung cancer
    Ganguly, Arghya
    Yoo, Euna
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2022, 43 (06) : 536 - 537
  • [4] Sotorasib shows clinical benefits in KRASG12C colorectal cancer
    Di Lellis, Maddalena Angela
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2022, 60 (05):
  • [5] Sotorasib in KRASG12C mutated lung cancer: Can we rule out cracking KRAS led to worse overall survival?
    Oliver, Timothee
    Haslam, Alyson
    Prasad, Vinay
    TRANSLATIONAL ONCOLOGY, 2023, 28
  • [6] Sotorasib Tackles KRASG12C-Mutated Pancreatic Cancer
    Osterweil, Neil
    CANCER DISCOVERY, 2022, 12 (04) : 878 - 879
  • [7] Sotorasib/SHP2 inhibitors combo, KRASG12C(ON)I and RASMULTI(ON)I effectively target KRASG12C tumors developing secondary resistance to Sotorasib via KRASG12C amplification
    Solanki, Hitendra S.
    Imbody, Denis
    Desai, Bina
    Kato, Ryoji
    Stewart, Paul A.
    Stern, Yaakov
    Majumder, Anurima
    Bridenstine, Liznair
    Sarca, Bhaswati
    Miroshnychenko, Dada
    Aronchik, Ida
    Marusyk, Andriy
    Haura, Eric B.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [8] KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
    Hong, David S.
    Fakih, Marwan G.
    Strickler, John H.
    Desai, Jayesh
    Durm, Gregory A.
    Shapiro, Geoffrey I.
    Falchook, Gerald S.
    Price, Timothy J.
    Sacher, Adrian
    Denlinger, Crystal S.
    Bang, Yung-Jue
    Dy, Grace K.
    Krauss, John C.
    Kuboki, Yasutoshi
    Kuo, James C.
    Coveler, Andrew L.
    Park, Keunchil
    Kim, Tae Won
    Barlesi, Fabrice
    Munster, Pamela N.
    Ramalingam, Suresh S.
    Burns, Timothy F.
    Meric-Bernstam, Funda
    Henary, Haby
    Ngang, Jude
    Ngarmchamnanrith, Gataree
    Kim, June
    Houk, Brett E.
    Canon, Jude
    Lipford, J. Russell
    Friberg, Gregory
    Lito, Piro
    Govindan, Ramaswamy
    Li, Bob T.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (13): : 1207 - 1217
  • [9] A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC
    Malhotra, J.
    Li, X.
    Palmer, J.
    Synold, T. W.
    Mohanty, A.
    Singhal, S.
    Kulkarni, P.
    Salgia, R.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S659 - S660
  • [10] Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancer
    Chour, Ali
    Toffart, Anne-Claire
    Berton, Elodie
    Duruisseaux, Michael
    FRONTIERS IN ONCOLOGY, 2024, 14
12345